AI in healthcare is accelerating fast—but adoption without governance is risk. In this conversation, oncology and health policy leaders break down how clinicians and health systems should evaluate emerging AI tools: what FDA clearance vs approval really means, why “not FDA-approved” doesn’t automatically mean unsafe, and how laboratory-developed tests (LDTs) are already embedded in everyday care. We also explore real-world evidence, model drift, and why implementation—not innovation—is the true bottleneck for safe scale. If you’re assessing AI in imaging, diagnostics, clinical decision support, or workflow automation, this is your framework for asking smarter questions and protecting patients.

Digital twins are moving from engineering into healthcare and the implications are profound. From oncology decision-making to clinical trials and personalized medicine, virtual human twins could reshape how clinicians predict outcomes, reduce toxicity, and tailor treatment. Dr. Sanjay Juneja and Dr. Doug Flora are joined by digital twin leaders Jim St. Clair and Professor James Fargason to explore how real-time data, AI, and system-level modeling can move medicine beyond population averages toward individualized care. This conversation unpacks what a true digital twin requires, why data quality and interoperability matter, and how digital twins may accelerate drug development, improve trial design, and reduce moral injury for clinicians.

Continuous monitoring is reshaping oncology. CEO of AION Biosystems, Sam Barend, joins Dr. Sanjay Juneja, Dr. Douglas Flora, and Dr. David Penberthy to explore how long‑term physiologic tracking, AI‑driven insights, and clinically validated wearables are improving outcomes for patients at high risk of complications. The conversation highlights FDA pathways, reimbursement realities, and the promise of simpler, signal‑focused monitoring that detects patterns earlier and supports safer treatment continuity.

Cancer care isn't what it used to be—and that's exactly why Dr. Douglas Flora just wrote a book about it. Are you ready to understand how AI is transforming oncology? In this episode of AI and Healthcare, host Dr. Sanjay Juneja and co-hosts Dr. Douglas Flora and Dr. Deborah Pat are joined by special guest Dr. Chadi Nabhan—author, educator, and passionate advocate for cancer education—to discuss Doug's newly released book on AI in cancer care, currently #1 in oncology on Amazon. Doug wrote it because he feels "desperate" to share how dramatically cancer treatment is changing. The physicians reflect on how far oncology has come from mixing chemotherapy by hand to AI-powered precision medicine. Whether you're a healthcare professional, cancer survivor, or curious about AI in medicine, this conversation offers an honest look at where oncology is headed. New episodes every two weeks.

AI is changing everything from policy to the patient room. In this AI&H roundtable, Dr. Doug Flora, a leading voice in oncology innovation, joins Dr. Sanjay Juneja, Dr. Debra Patt, and Mika Newton to tackle what’s really holding back AI adoption in healthcare. They explore Medicare’s AI prior auth model, the role of clinical decision support, and why strong change management is the linchpin of real progress. Dr. Flora shares leadership lessons and insights from the front lines.

Healthcare is shifting fast, and AI is at the center of the storm. In this powerful roundtable, Dr. Sanjay Juneja hosts xCures CEO Mika Newton, Dr. Debra Patt of Texas Oncology, and Dr. Jason Hill of Ochsner Health to break down how AI is already reshaping access, risk, and care delivery. From ambient scribes to open-source models, from liability concerns to mental health triage—this conversation covers what matters.

What is patient design, and why does it matter in modern healthcare? Dr. Bertalan Meskó, Director of The Medical Futurist Institute, explains why patient involvement is critical to innovation and trust. Patient-centered design shifts the model from making decisions for patients to making decisions with them. This co-creation approach ensures better outcomes and more effective digital health solutions.

Could AI soon become a required element of value-based care? Dr. Stephen Speicher from Flatiron Health explores a near-future scenario where insurers may require AI tools to be used in clinical workflows to qualify for reimbursement.

Should patients be able to opt out of AI in their care? Dr. Stephen Speicher, Head of Clinical Oncology and Safety at Flatiron Health, dives into the evolving ethics of informed consent as AI becomes increasingly embedded in medical workflows. From regulatory trends to future standards of care, he examines how clinicians and patients can navigate transparency, autonomy, and shared responsibility.

What if your future self could guide your decisions today? Dr. Bertalan Mesko, Director of The Medical Futurist Institute, shares a surprisingly effective strategy: vision writing. By imagining yourself in the future and striking “deals” with future versions of yourself, you can create emotional clarity and motivation in the present.